Search

Your search keyword '"Minichini, C."' showing total 162 results
Start Over Author "Minichini, C."
162 results on '"Minichini, C."'

1. Genetic Variability in Patients with HCV-Related Hepatocellular Carcinoma

Author

Pisaturo M, Di Fraia A, Occhiello L, Minichini C, Starace M, Iodice V, Farella N, Stanzione M, and Coppola N

Subjects
hepatocellular carcinoma, hcv, viral variability, chronic hepatitis c, chronic infection c, core region, ns5a region, ns3 region, aa substitutions, phylogenesis, Infectious and parasitic diseases, RC109-216
Abstract

Mariantonietta Pisaturo,1 Alessandra Di Fraia,1 Laura Occhiello,1 Carmine Minichini,1 Mario Starace,1 Valentina Iodice,2 Nunzia Farella,2 Maria Stanzione,1 Nicola Coppola1 1Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania “L. Vanvitelli”, Naples, Italy; 2IX Infectious Disease Unit, AORN dei Colli, Naples, ItalyCorrespondence: Nicola CoppolaDepartment of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Via L. Armanni 5, Naples, 80131, ItalyTel +39 081 5666223Fax +39 081 5666013Email nicola.coppola@unicampania.itBackground: The present paper evaluates the genetic variability of HCV in patients with hepatocellular carcinoma (HCC).Methods: Amino acid substitutions (aas) in NS3, NS5A and core regions were analyzed in 17 patients with HCC (Cases) and 13 without HCC (Controls), all naïve to DAAs. For the Cases, a sample of neoplastic liver tissue, non-neoplastic liver tissue and a serum sample were collected; for the Controls, a sample of liver tissue was collected. Sanger sequencing of three regions was performed using homemade protocols.Results: Phylogenetic trees showed that there was no difference in the virus populations in the three compartments analyzed for the three HCV regions in patients with HCC. Low variability and no difference between the Cases and Controls were observed in the core and NS5A regions; however, in the NS3 region, a higher variability was observed in the Cases. No difference was observed in the core region between Cases and Controls. In NS3, aa substitutions at positions 103 and 122 were more frequently found in Cases than Controls (in both cases 50% vs 9.1%, p< 0.05); moreover, aas in positions 32, 44 (p=0.035 for both), 79 (p=0.008) and 121 (p=0.018) were observed in the Cases and absent in the Controls. Finally, considering the NS5A region, aa substitutions at positions 37 and 54 were more frequently identified in the Cases than the Controls, but without statistical significance.Conclusion: These data may suggest a higher aa variability in patients with HCC than in those without, especially in the NS3 region.Keywords: hepatocellular carcinoma, HCV, viral variability, chronic hepatitis C, chronic infection C, core region, NS5A region, NS3 region, aa substitutions, phylogenesis

Published
2021

3. Assessment and Comparison of Two Serological Approaches for the Surveillance of Health Workers Exposed to SARS-CoV-2

Author

Russo A, Calò F, Di Fraia A, Starace M, Minichini C, Gentile V, Angelillo IF, and Coppola N

Subjects
health workers, covid-19, sars-cov-2, anti-igg sar-cov-2, active surveillance, Infectious and parasitic diseases, RC109-216
Abstract

Antonio Russo,1 Federica Calò,1 Alessandra Di Fraia,1 Mario Starace,1 Carmine Minichini,1 Valeria Gentile,1 Italo Francesco Angelillo,2 Nicola Coppola1 On behalf of the Vanvitelli-COVID-19 Group1Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania, Naples, Italy; 2Department of Experimental Medicine, University of Campania, Naples, ItalyCorrespondence: Nicola Coppola Department of Mental Health and Public Medicine, Section of Infectious DiseasesUniversity of Campania, via: L. Armanni 5, Naples 80131, ItalyTel +39 0815666719Fax +39 0815666013Email nicola.coppola@unicampania.itBackground and Aim: The aim of the present study was to assess the diagnostic performance of an LFA compared with an ELISA test in a cohort of HWs operating in a COVID-19 unit of a teaching hospital in southern Italy.Methods: We performed an observational, prospective, interventional study including 65 COVID-19 unit personnel. On a total of 196 serum samples (at least 2 serum samples for each HW), LFA and ELISA tests for SARS-COV-2 IgG and IgM were performed. Also, 32 serum samples of SARS-CoV-2 RNA positive patients at least 21 days before sampling, and 30 serum samples of patients obtained up to November 2019, before COVID-19 outbreak in China, were used as positive and negative controls, respectively.Findings: Of the 65 HWs enrolled, 6 were positive in LFA; overall, of the 196 serum samples, 20 were positive in LFA. All ELISA tests performed on serum samples collected from HWs were negative. The specificity of LFAs was 90.77% considering the 65 HWs and 89.80% considering all the 196 health workers serum samples analyzed. Considering the data on HWs, ELISA test for SARS-COV-2 antibodies showed a specificity of 100%, including all the 196 serum samples collected, and 100% including the 65 HWs. The ELISA and LFAs performed after 21 days last COVID-19 patient was discharged were all negative.Conclusion: LFAs compared to ELISA tests result in less specificity, considering COVID-19 negative personnel and patients. Thus, LFAs seem to be not adequate in the active surveillance of HWs.Keywords: health workers, COVID-19, SARS-CoV-2, anti-IgG SAR-COV-2, active surveillance

Published
2020

4. Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review

Author

Russo A, Minichini C, Starace M, Astorri R, Calò F, and Coppola N

Subjects
covid-19, sars-cov-2, laboratory diagnosis, serological test, pcr, Infectious and parasitic diseases, RC109-216
Abstract

Antonio Russo, Carmine Minichini, Mario Starace, Roberta Astorri, Federica Calò, Nicola Coppola On behalf of the Vanvitelli COVID-19 groupDepartment of Mental Health and Public Medicine, Infectious Diseases Unit, University of Campania Luigi Vanvitelli, Naples, ItalyCorrespondence: Nicola CoppolaDepartment of Mental Health and Public Medicine, Infectious Diseases Unit, University of Campania Luigi Vanvitelli, Via: L. Armanni 5, Naples 80131, ItalyTel +39 0815666719Fax +39 0815666013Email nicola.coppola@unicampania.itAbstract: The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the related disease (COVID-19) has spread rapidly to pandemic proportions, increasing the demands on healthcare systems for the containment and management of COVID-19. One of the critical issues to be addressed is the improvement in laboratory diagnosis and screening of large portions of the population to stop the virus spreading. Currently, the laboratory diagnosis of SARS-CoV-2 infection and the related disease is based on the research of viral RNA with rt-PCR methods in upper and lower respiratory airways. Serological tests to detect SARS-CoV-2 antibodies could help physicians and healthcare workers to support COVID-19 diagnosis and follow-up and perform population screening. Our review, using MEDLINE and EMBASE, summarizes the current knowledge of direct and serological tests performed to research RNA, antigens, or antibodies for SARS-CoV-2, evaluating the advantages and drawbacks for specific tests.Keywords: COVID-19, SARS-CoV-2, laboratory diagnosis, serological test, PCR

Published
2020

5. Mutation model for nucleotide sequences based on crystal basis

Author

Minichini, C. and Sciarrino, A.

Subjects
Quantitative Biology - Biomolecules, Quantitative Biology - Other Quantitative Biology
Abstract

A nucleotides sequence is identified, in the two (four) letters alphabet, by the the labels of a vector state of an irreducible representation of U_q(sl(2)) (U_q(sl(2) + sl(2))), in the limit q -> 0. A master equation for the distribution function is written, where the intensity of the one-spin flip is assumed to depend from the variation of the labels of the state. In the two letters approximation, the numerically computed equilibrium distribution for short sequences is nicely fitted by a Yule distribution, which is the observed distribution of the ranked short oligonucleotides frequency in DNA. The four letter alphabet description, applied to the codons, is able to reproduce the form of the fitted rank ordered usage frequencies distribution., Comment: 27 pages, 9 figures

Published
2005

6. Mutation model for oligonucleotides fitting a Yule distribution

Author

Minichini, C. and Sciarrino, A.

Subjects
Quantitative Biology - Biomolecules, Condensed Matter - Other Condensed Matter, Quantitative Biology - Other Quantitative Biology
Abstract

A spin chain, describing a nucleotides sequence, is identified by the labels of a vector state of an irreducible representation of U_q->0(sl2). A master equation for the distribution function is written, where the intensity of the one-spin flip is assumed to depend on the variation of the labels. The numerically computed equilibrium distribution is nicely fitted by a Yule distribution, which is the observed distribution of the ranked short oligonucleotides frequency in DNA, Comment: 13 pages, 4 figures

Published
2004

7. Quantum spin model fitting the Yule distribution of oligonucleotides in DNA

Author

Minichini, C. and Sciarrino, A.

Subjects
Quantum Physics, Quantitative Biology - Biomolecules
Abstract

A quantum spin chain is identified by the labels of a vector state of a Kashiwara crystal basis. The intensity of the one-spin flip is assumed to depend from the variation of the labels. The rank ordered plot of the numerically computed, averaged in time, transition probabilities is nicely fitted by a Yule distribution, which is the observed distribution of the ranked short oligonucleotides frequency in DNA., Comment: 12 pages, 4 figures

Published
2004

10. Assessment and Comparison of Two Serological Approaches for the Surveillance of Health Workers Exposed to SARS-CoV-2

Author

Calò F, Di Fraia A, Starace M, Minichini C, Gentile V, Angelillo IF, Coppola N, Russo A, Calò, F, Di Fraia, A, Starace, M, Minichini, C, Gentile, V, Angelillo, If, Coppola, N, and Russo, A

Subjects
health workers, sars-cov-2, covid-19, active surveillance, lcsh:RC109-216, anti-igg sar-cov-2, lcsh:Infectious and parasitic diseases
Abstract

Antonio Russo,1 Federica Calò,1 Alessandra Di Fraia,1 Mario Starace,1 Carmine Minichini,1 Valeria Gentile,1 Italo Francesco Angelillo,2 Nicola Coppola1 On behalf of the Vanvitelli-COVID-19 Group1Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania, Naples, Italy; 2Department of Experimental Medicine, University of Campania, Naples, ItalyCorrespondence: Nicola Coppola Department of Mental Health and Public Medicine, Section of Infectious DiseasesUniversity of Campania, via: L. Armanni 5, Naples 80131, ItalyTel +39 0815666719Fax +39 0815666013Email nicola.coppola@unicampania.itBackground and Aim: The aim of the present study was to assess the diagnostic performance of an LFA compared with an ELISA test in a cohort of HWs operating in a COVID-19 unit of a teaching hospital in southern Italy.Methods: We performed an observational, prospective, interventional study including 65 COVID-19 unit personnel. On a total of 196 serum samples (at least 2 serum samples for each HW), LFA and ELISA tests for SARS-COV-2 IgG and IgM were performed. Also, 32 serum samples of SARS-CoV-2 RNA positive patients at least 21 days before sampling, and 30 serum samples of patients obtained up to November 2019, before COVID-19 outbreak in China, were used as positive and negative controls, respectively.Findings: Of the 65 HWs enrolled, 6 were positive in LFA; overall, of the 196 serum samples, 20 were positive in LFA. All ELISA tests performed on serum samples collected from HWs were negative. The specificity of LFAs was 90.77% considering the 65 HWs and 89.80% considering all the 196 health workers serum samples analyzed. Considering the data on HWs, ELISA test for SARS-COV-2 antibodies showed a specificity of 100%, including all the 196 serum samples collected, and 100% including the 65 HWs. The ELISA and LFAs performed after 21 days last COVID-19 patient was discharged were all negative.Conclusion: LFAs compared to ELISA tests result in less specificity, considering COVID-19 negative personnel and patients. Thus, LFAs seem to be not adequate in the active surveillance of HWs.Keywords: health workers, COVID-19, SARS-CoV-2, anti-IgG SAR-COV-2, active surveillance

Published
2020

12. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

Author

Di Maio, V, Barbaliscia, S, Teti, E, Fiorentino, G, Milana, M, Paolucci, S, Pollicino, T, Morsica, G, Starace, M, Bruzzone, B, Gennari, W, Micheli, V, Yu La Rosa, K, Foroghi, L, Calvaruso, V, Lenci, I, Polilli, E, Babudieri, S, Aghemo, A, Raimondo, G, Sarmati, L, Coppola, N, Pasquazzi, C, Baldanti, F, Parruti, G, Perno, C, Angelico, M, Craxi, A, Andreoni, M, Ceccherini-Silberstein, F, Andreone, P, Aragri, M, Bertoli, A, Boeri, E, Brancaccio, G, Brunetto, M, Callegaro, A, Cenderello, G, Cento, V, Ciaccio, A, Ciancio, A, Cuomo, N, De Santis, A, Di Biagio, A, Di Marco, V, Di Perri, G, Di Stefano, M, Gaeta, G, Ghisetti, V, Gulminetti, R, Lampertico, P, Landonio, S, Lichtner, M, Lleo, A, Maida, I, Marenco, S, Masetti, C, Mastroianni, C, Minichini, C, Milano, E, Monno, L, Novati, S, Pace Palitti, V, Paternoster, C, Pellicelli, A, Pieri, A, Puoti, M, Rizzardini, G, Ruggiero, T, Rossetti, B, Sangiovanni, V, Santantonio, T, Taliani, G, Toniutto, P, Vullo, V, Zazzi, M, Di Maio V. C., Barbaliscia S., Teti E., Fiorentino G., Milana M., Paolucci S., Pollicino T., Morsica G., Starace M., Bruzzone B., Gennari W., Micheli V., Yu La Rosa K., Foroghi L., Calvaruso V., Lenci I., Polilli E., Babudieri S., Aghemo A., Raimondo G., Sarmati L., Coppola N., Pasquazzi C., Baldanti F., Parruti G., Perno C. F., Angelico M., Craxi A., Andreoni M., Ceccherini-Silberstein F., Andreone P., Aragri M., Bertoli A., Boeri E., Brancaccio G., Brunetto M., Callegaro A. P., Cenderello G., Cento V., Ciaccio A., Ciancio A., Cuomo N., De Santis A., Di Biagio A., Di Marco V., Di Perri G., Di Stefano M. A., Gaeta G. B., Ghisetti V., Gulminetti R., Lampertico P., Landonio S., Lichtner M., Lleo A., Maida I., Marenco S., Masetti C., Mastroianni C., Minichini C., Milano E., Monno L., Novati S., Pace Palitti V., Paternoster C., Pellicelli A., Pieri A., Puoti M., Rizzardini G., Ruggiero T., Rossetti B., Sangiovanni V., Santantonio T., Taliani G., Toniutto P., Vullo V., Zazzi M., Di Maio, V, Barbaliscia, S, Teti, E, Fiorentino, G, Milana, M, Paolucci, S, Pollicino, T, Morsica, G, Starace, M, Bruzzone, B, Gennari, W, Micheli, V, Yu La Rosa, K, Foroghi, L, Calvaruso, V, Lenci, I, Polilli, E, Babudieri, S, Aghemo, A, Raimondo, G, Sarmati, L, Coppola, N, Pasquazzi, C, Baldanti, F, Parruti, G, Perno, C, Angelico, M, Craxi, A, Andreoni, M, Ceccherini-Silberstein, F, Andreone, P, Aragri, M, Bertoli, A, Boeri, E, Brancaccio, G, Brunetto, M, Callegaro, A, Cenderello, G, Cento, V, Ciaccio, A, Ciancio, A, Cuomo, N, De Santis, A, Di Biagio, A, Di Marco, V, Di Perri, G, Di Stefano, M, Gaeta, G, Ghisetti, V, Gulminetti, R, Lampertico, P, Landonio, S, Lichtner, M, Lleo, A, Maida, I, Marenco, S, Masetti, C, Mastroianni, C, Minichini, C, Milano, E, Monno, L, Novati, S, Pace Palitti, V, Paternoster, C, Pellicelli, A, Pieri, A, Puoti, M, Rizzardini, G, Ruggiero, T, Rossetti, B, Sangiovanni, V, Santantonio, T, Taliani, G, Toniutto, P, Vullo, V, Zazzi, M, Di Maio V. C., Barbaliscia S., Teti E., Fiorentino G., Milana M., Paolucci S., Pollicino T., Morsica G., Starace M., Bruzzone B., Gennari W., Micheli V., Yu La Rosa K., Foroghi L., Calvaruso V., Lenci I., Polilli E., Babudieri S., Aghemo A., Raimondo G., Sarmati L., Coppola N., Pasquazzi C., Baldanti F., Parruti G., Perno C. F., Angelico M., Craxi A., Andreoni M., Ceccherini-Silberstein F., Andreone P., Aragri M., Bertoli A., Boeri E., Brancaccio G., Brunetto M., Callegaro A. P., Cenderello G., Cento V., Ciaccio A., Ciancio A., Cuomo N., De Santis A., Di Biagio A., Di Marco V., Di Perri G., Di Stefano M. A., Gaeta G. B., Ghisetti V., Gulminetti R., Lampertico P., Landonio S., Lichtner M., Lleo A., Maida I., Marenco S., Masetti C., Mastroianni C., Minichini C., Milano E., Monno L., Novati S., Pace Palitti V., Paternoster C., Pellicelli A., Pieri A., Puoti M., Rizzardini G., Ruggiero T., Rossetti B., Sangiovanni V., Santantonio T., Taliani G., Toniutto P., Vullo V., and Zazzi M.

Abstract

Aim: This study aimed to investigate the role of resistance-associated substitutions (RASs) to direct-acting-antivirals (DAAs) in HCV genotype 3 (GT3). Methods: Within the Italian VIRONET-C network, a total of 539 GT3-infected patients (417 DAA-naïve and 135 DAA-failures, of them, 13 at both baseline and failure) were analysed. Sanger sequencing of NS3/NS5A/NS5B was performed following home-made protocols. Results: The majority of patients were male (79.4%), 91.4% were injection drug users, 49.3% were cirrhotic and 13.9% were HIV co-infected. Phylogenetic analysis classified sequences as GT3a-b-g-h (98%-0.4%-0.2%-1.2%) respectively. Overall, 135 patients failed a DAA regimen: sofosbuvir (SOF)/daclatasvir (DCV) or velpatasvir (VEL)±ribavirin (RBV) (N = 91/15) and glecaprevir (G)/pibrentasvir (P) (N = 9). Moreover, 14.8% of patients were treated with suboptimal regimens for GT3: 3D ± RBV (Paritaprevir/r + Ombitasvir+Dasabuvir, N = 15), SOF + Simeprevir (SIM) (N = 1) or SOF/Ledipasvir (LDV) ± RBV (N = 4). RAS prevalence was 15.8% in DAA-naïve patients. At failure, 81.5% patients showed at least one RAS: 11/25 (44.0%) in NS3, 109/135 (80.7%) in NS5A, 7/111 (6.3%) in NS5B SOF-failures. In NS5A-failures, Y93H RAS was the most prevalent (68.5% vs 5.1% DAA-naïve, P <.001) followed by A30K (12.7% vs 2.8% in DAA-naïve, P <.001). Analysing baseline samples, a higher prevalence of NS5A-RASs was observed before treatment in DAA-failures (5/13, 38.5%) vs DAA-naïves (61/393, 15.5%, P =.04). Regarding 228 DAA-naïve patients with an available outcome, 93.9% achieved a SVR. Interestingly, patients with baseline Y93H and/or A30K had SVR rate of 72.2% vs 95.7% for patients without NS5A-RASs (P =.002). Conclusions: In this real-life GT3 cohort, the majority of failures harboured resistant variants carrying NS5A-RASs, the most frequent being Y93H. The presence of natu

Published
2021

13. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

Author

Di Maio, V. C., Barbaliscia, S., Teti, E., Fiorentino, G., Milana, M., Paolucci, S., Pollicino, T., Morsica, G., Starace, M., Bruzzone, B., Gennari, W., Micheli, V., Yu La Rosa, K., Foroghi, L., Calvaruso, V., Lenci, I., Polilli, E., Babudieri, S., Aghemo, A., Raimondo, G., Sarmati, L., Coppola, N., Pasquazzi, C., Baldanti, F., Parruti, G., Perno, C. F., Angelico, M., Craxi, A., Andreoni, M., Ceccherini-Silberstein, F., Andreone, P., Aragri, M., Bertoli, A., Boeri, E., Brancaccio, G., Brunetto, M., Callegaro, A. P., Cenderello, G., Cento, V., Ciaccio, A., Ciancio, A., Cuomo, N., De Santis, A., Di Biagio, A., Di Marco, V., Di Perri, G., Di Stefano, M. A., Gaeta, G. B., Ghisetti, V., Gulminetti, R., Lampertico, P., Landonio, S., Lichtner, M., Lleo, A., Maida, I., Marenco, S., Masetti, C., Mastroianni, C., Minichini, C., Milano, E., Monno, L., Novati, S., Pace Palitti, V., Paternoster, C., Pellicelli, A., Pieri, A., Puoti, M., Rizzardini, G., Ruggiero, T., Rossetti, B., Sangiovanni, V., Santantonio, T., Taliani, G., Toniutto, P., Vullo, V., Zazzi, M., Di Maio, V, Barbaliscia, S, Teti, E, Fiorentino, G, Milana, M, Paolucci, S, Pollicino, T, Morsica, G, Starace, M, Bruzzone, B, Gennari, W, Micheli, V, Yu La Rosa, K, Foroghi, L, Calvaruso, V, Lenci, I, Polilli, E, Babudieri, S, Aghemo, A, Raimondo, G, Sarmati, L, Coppola, N, Pasquazzi, C, Baldanti, F, Parruti, G, Perno, C, Angelico, M, Craxi, A, Andreoni, M, Ceccherini-Silberstein, F, Andreone, P, Aragri, M, Bertoli, A, Boeri, E, Brancaccio, G, Brunetto, M, Callegaro, A, Cenderello, G, Cento, V, Ciaccio, A, Ciancio, A, Cuomo, N, De Santis, A, Di Biagio, A, Di Marco, V, Di Perri, G, Di Stefano, M, Gaeta, G, Ghisetti, V, Gulminetti, R, Lampertico, P, Landonio, S, Lichtner, M, Lleo, A, Maida, I, Marenco, S, Masetti, C, Mastroianni, C, Minichini, C, Milano, E, Monno, L, Novati, S, Pace Palitti, V, Paternoster, C, Pellicelli, A, Pieri, A, Puoti, M, Rizzardini, G, Ruggiero, T, Rossetti, B, Sangiovanni, V, Santantonio, T, Taliani, G, Toniutto, P, Vullo, V, Zazzi, M, Di Maio, Vc, Perno, Cf, Craxì, A, Di Maio V.C., Barbaliscia S., Teti E., Fiorentino G., Milana M., Paolucci S., Pollicino T., Morsica G., Starace M., Bruzzone B., Gennari W., Micheli V., Yu La Rosa K., Foroghi L., Calvaruso V., Lenci I., Polilli E., Babudieri S., Aghemo A., Raimondo G., Sarmati L., Coppola N., Pasquazzi C., Baldanti F., Parruti G., Perno C.F., Angelico M., Craxi A., Andreoni M., Ceccherini-Silberstein F., Andreone P., Aragri M., Bertoli A., Boeri E., Brancaccio G., Brunetto M., Callegaro A.P., Cenderello G., Cento V., Ciaccio A., Ciancio A., Cuomo N., De Santis A., Di Biagio A., Di Marco V., Di Perri G., Di Stefano M.A., Gaeta G.B., Ghisetti V., Gulminetti R., Lampertico P., Landonio S., Lichtner M., Lleo A., Maida I., Marenco S., Masetti C., Mastroianni C., Minichini C., Milano E., Monno L., Novati S., Pace Palitti V., Paternoster C., Pellicelli A., Pieri A., Puoti M., Rizzardini G., Ruggiero T., Rossetti B., Sangiovanni V., Santantonio T., Taliani G., Toniutto P., Vullo V., and Zazzi M.

Subjects
Male, Sofosbuvir, Sustained Virologic Response, Drug Resistance, Hepacivirus, Viral Nonstructural Proteins, Gastroenterology, Settore MED/06, direct-acting antivirals, failure, genotype 3, HCV, resistance, chemistry.chemical_compound, 0302 clinical medicine, Medicine, Viral, Chronic, Phylogeny, Dasabuvir, hcv, virus diseases, Hepatitis C, Pibrentasvir, Italy, 030220 oncology & carcinogenesis, Combination, Drug Therapy, Combination, 030211 gastroenterology & hepatology, Female, medicine.drug, Ledipasvir, medicine.medical_specialty, Daclatasvir, Genotype, Antiviral Agents, Drug Resistance, Viral, Humans, Hepatitis C, Chronic, 03 medical and health sciences, Drug Therapy, Internal medicine, Antiviral Agent, direct-acting antiviral, Hepaciviru, Hepatology, business.industry, Viral Nonstructural Protein, Glecaprevir, direct acting antivirals, Regimen, chemistry, Paritaprevir, business
Abstract

Aim: This study aimed to investigate the role of resistance-associated substitutions (RASs) to direct-acting-antivirals (DAAs) in HCV genotype 3 (GT3). Methods: Within the Italian VIRONET-C network, a total of 539 GT3-infected patients (417 DAA-naïve and 135 DAA-failures, of them, 13 at both baseline and failure) were analysed. Sanger sequencing of NS3/NS5A/NS5B was performed following home-made protocols. Results: The majority of patients were male (79.4%), 91.4% were injection drug users, 49.3% were cirrhotic and 13.9% were HIV co-infected. Phylogenetic analysis classified sequences as GT3a-b-g-h (98%-0.4%-0.2%-1.2%) respectively. Overall, 135 patients failed a DAA regimen: sofosbuvir (SOF)/daclatasvir (DCV) or velpatasvir (VEL)±ribavirin (RBV) (N=91/15) and glecaprevir (G)/pibrentasvir (P) (N=9). Moreover, 14.8% of patients were treated with suboptimal regimens for GT3: 3D±RBV (Paritaprevir/r+Ombitasvir+Dasabuvir, N=15), SOF+Simeprevir (SIM) (N=1) or SOF/Ledipasvir (LDV)±RBV (N=4). RAS prevalence was 15.8% in DAA-naïve patients. At failure, 81.5% patients showed at least one RAS: 11/25 (44.0%) in NS3, 109/135 (80.7%) in NS5A, 7/111 (6.3%) in NS5B SOF-failures. In NS5A-failures, Y93H RAS was the most prevalent (68.5% vs 5.1% DAA-naïve, P&nbsp

Published
2021

14. Prevalence and Characterization of Resistance Profiles of “Unusual” HCV Subtypes in Italy within the Italian Resistance Network Vironet C

Author

Khalili, O. El, Chenwi, C., Di Maio, V.C., Alkhatib, M., Teti, E., Bertoli, A., Paolucci, S., Caudai, C., Pollicino, T., Coppola, N., Bruzzone, B., Monno, L., Khan, S., Minichini, C., Torre, G., Bresciani, L., Parruti, G., Palitti, V. Pace, Micheli, V., Callegaro, A.P., Galli, S., Di Marco, V., Mulas, T., Rossetti, B., Zignego, A.L., Pieri, A., Novazzi, F., Milana, M., Carioti, L., Ciotti, M., Lenci, I., Ansaldo, L., Pellicelli, A., Moretti, A., Morisco, F., Gulminetti, R., Novati, S., Lichtner, M., Mastroianni, C., Di Lorenzo, F., Andreone, P., Marenco, S., Taliani, G., Hasson, H., Nicolini, L.A., Magni, C.F., Paternoster, C., Licata, A., Babudieri, S., Malagnino, V., Francioso, S., Degasperi, E., Quartini, G., Pasquazzi, C., Iapadre, N., Cozzolongo, R., Sangiovanni, V., Schiavo, R., Soria, A., Tacconi, D., Blanc, P.L., Lampertico, P., Baldanti, F., Raimondo, G., Baiocchi, L., Andreoni, M., Perno, C.F., Puoti, M, Sarmati, L., Craxì, A., Zazzi, M., and Ceccherini-Silberstein, F.

Published
2024
Full Text
View/download PDF

16. Cardiovascular System in COVID-19: Simply a Viewer or a Leading Actor?

Author

Mottola F. F., Verde N., Ricciolino R., Di Mauro M., Migliaccio M. G., Carfora V., Spiniello G., Coppola N., Macera M., Calo F., Sagnelli C., Monari C., Martini S., Stornaiuolo G., Stanzione M., De Pascalis S., Cascone A., Bianco A., Gentile V., Camaioni C., De Angelis G., Marino G., Astorri R., Starace M., Minichini C., Di Fraia A., De Sio I., Niosi M., Borrelli S., Celia B., Ceparano M., Cirillo S., De Luca M., Mazzeo G., Paoli G., Russo M. G., Russo A., Mottola, F. F., Verde, N., Ricciolino, R., Di Mauro, M., Migliaccio, M. G., Carfora, V., Spiniello, G., Coppola, N., Macera, M., Calo, F., Sagnelli, C., Monari, C., Martini, S., Stornaiuolo, G., Stanzione, M., De Pascalis, S., Cascone, A., Bianco, A., Gentile, V., Camaioni, C., De Angelis, G., Marino, G., Astorri, R., Starace, M., Minichini, C., Di Fraia, A., De Sio, I., Niosi, M., Borrelli, S., Celia, B., Ceparano, M., Cirillo, S., De Luca, M., Mazzeo, G., Paoli, G., Russo, M. G., and Russo, A.

Subjects
medicine.medical_specialty, Myocarditis, heart failure, Review, Disease, 030204 cardiovascular system & hematology, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Pericarditis, 0302 clinical medicine, Diabetes mellitus, Pandemic, medicine, myocardial injury, 030212 general & internal medicine, lcsh:Science, Intensive care medicine, Ecology, Evolution, Behavior and Systematics, business.industry, Mechanism (biology), SARS-CoV-2 infection, Paleontology, Cancer, medicine.disease, Space and Planetary Science, Heart failure, cardiovascular system, lcsh:Q, business
Abstract

As of January 2020, a new pandemic has spread from Wuhan and caused thousands of deaths worldwide. Several studies have observed a relationship between coronavirus disease (COVID-19) infection and the cardiovascular system with the appearance of myocardial damage, myocarditis, pericarditis, heart failure and various arrhythmic manifestations, as well as an increase in thromboembolic risk. Cardiovascular manifestations have been highlighted especially in older and more fragile patients and in those with multiple cardiovascular risk factors such as cancer, diabetes, obesity and hypertension. In this review, we will examine the cardiac involvement associated with SARS-CoV-2 infection, focusing on the pathophysiological mechanism underlying manifestations and their clinical implication, taking into account the main scientific papers published to date.

Published
2020
Full Text
View/download PDF

17. Quantitative HBeAg varies across the different phases of HBV infection, and can predict treatment outcome in the setting of HBV-reactivation driven by iatrogenic immunosuppression

Author

Piermatteo, L., primary, Salpini, R., additional, Alkhatib, M., additional, Bertoli, A., additional, Iuvara, A., additional, De Cristofaro, M., additional, Cappiello, G., additional, Cerva, C., additional, Minichini, C., additional, Pisaturo, M., additional, Starace, M., additional, Coppola, N., additional, Fontana, C., additional, Sarmati, L., additional, Andreoni, M., additional, Angelico, M., additional, Grelli, S., additional, Silberstein, F. Ceccherini, additional, Perno, C.F., additional, and Svicher, V., additional

Published
2020
Full Text
View/download PDF

18. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

Author

Barbaliscia, S., primary, Di Maio, V.C., additional, Fabeni, L., additional, Teti, E., additional, Paolucci, S., additional, Minichini, C., additional, Aragri, M., additional, Rosa, K. Yu La, additional, Carioti, L., additional, Pasquazzi, C., additional, Milana, M., additional, Foroghi, L., additional, Pollicino, T., additional, Licata, A., additional, Pieri, A., additional, Palitti, V. Pace, additional, Bruzzone, B., additional, Micheli, V., additional, Bertoli, A., additional, Baiocchi, L., additional, Callegaro, A.P., additional, Pellicelli, A., additional, Morisco, F., additional, Gulminetti, R., additional, Novati, S., additional, Lichtner, M., additional, Mastroianni, C., additional, Di Lorenzo, F., additional, Andreone, P., additional, Rossetti, B., additional, Marenco, S., additional, Taliani, G., additional, Boeri, E., additional, Hasson, H., additional, Monno, L., additional, Nicolini, L.A., additional, Landonio, S., additional, Paternoster, C., additional, Puoti, M., additional, Babudieri, S., additional, Quartini, M., additional, Iapadre, N., additional, Cozzolongo, R., additional, Sangiovanni, V., additional, Parruti, G., additional, Sarmati, L., additional, Coppola, N., additional, Baldanti, F., additional, Marco, V. Di, additional, Zazzi, M., additional, Raimondo, G., additional, Angelico, M., additional, Perno, C.F., additional, Andreoni, M., additional, Craxì, A., additional, and Ceccherini-Silberstein, F., additional

Published
2020
Full Text
View/download PDF

19. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

Author

Di Maio, V.C., primary, Aragri, M., additional, Masetti, C., additional, Paolucci, S., additional, Bruzzone, B., additional, Degasperi, E., additional, Barbaliscia, S., additional, Pollicino, T., additional, Minichini, C., additional, Calvaruso, V., additional, Rendina, M., additional, Cento, V., additional, Teti, E., additional, Micheli, V., additional, Allice, T., additional, Polilli, E., additional, Palitti, V. Pace, additional, Landonio, S., additional, Lenci, I., additional, Francioso, S., additional, Donnarumma, L., additional, Nicolini, L.A., additional, Bertoli, A., additional, Starace, M., additional, Pasquazzi, C., additional, Callegaro, A.P., additional, Morisco, F., additional, Cenderello, G., additional, Marenco, S., additional, Gulminetti, R., additional, Novati, S., additional, Scuteri, A., additional, Andreone, P., additional, Galli, S., additional, Ciancio, A., additional, Sangiovanni, V., additional, Cuomo, N., additional, Raddi, A., additional, Gennari, W., additional, Boeri, E., additional, Morsica, G., additional, Hasson, H., additional, Borghi, V., additional, Maida, I., additional, Brunetto, M., additional, Colombatto, P., additional, Cozzolongo, R., additional, De Santis, A., additional, Lichtner, M., additional, Babudieri, S., additional, Biliotti, E., additional, Taliani, G., additional, Santantonio, T., additional, Di Stefano, M., additional, Paternoster, C., additional, Ganga, R., additional, Merli, M., additional, Rizzardini, G., additional, Pellicelli, A., additional, Giannelli, V., additional, Milano, E., additional, Mastroianni, C., additional, Licata, A., additional, Di Lorenzo, F., additional, Giorgini, A., additional, Sighinolfi, L., additional, Dentone, C., additional, Lleo, A., additional, Rossetti, B., additional, Beretta, I., additional, Cariti, G., additional, Ghisetti, V., additional, Lampertico, P., additional, Parruti, G., additional, Coppola, N., additional, Baldanti, F., additional, Gaeta, G.B., additional, Raimondo, G., additional, Puoti, M., additional, Zazzi, M., additional, Andreoni, M., additional, Angelico, M., additional, Perno, C.F., additional, Craxì, A., additional, and Ceccherini-Silberstein, F., additional

Published
2020
Full Text
View/download PDF

20. Hepatitis C late relapse in patients with directly acting antiviral-related sustained virological response at week 12

Author

Pisaturo M, Minichini C, Starace M, Caroprese M, Macera M, Brancaccio G, De Pascalis S, Santonicola A, Galeota Lanza A, Zampino R, Cotticelli G, Sagnelli E, Gaeta GB, Coppola N, Pisaturo, M, Minichini, C, Starace, M, Caroprese, M, Macera, M, Brancaccio, G, De Pascalis, S, Santonicola, A, Galeota Lanza, A, Zampino, R, Cotticelli, G, Sagnelli, E, Gaeta, Gb, and Coppola, N

Published
2018

21. HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era

Author

Minichini C, Starace M, DE PASCALIS, VILFREDO, Macera M, Occhiello L, Caroprese M, Vitrone M, Iovinella V, Guerrera B, Masarone M, Coppola N, Minichini, C, Starace, M, DE PASCALIS, Vilfredo, Macera, M, Occhiello, L, Caroprese, M, Vitrone, M, Iovinella, V, Guerrera, B, Masarone, M, and Coppola, N

Published
2018

22. VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS

Author

Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Adinolfi LE, Claar E, Precone D, Stornaiuolo G, Stanzione M, Ascione T, Caroprese M, Zampino R, Parrilli G, Gentile I, Brancaccio G, Iovinella V, Martini S, Masarone M, Fontanella L, Masiello A, Sagnelli E, Punzi R, Salomone Megna A, Santoro R, Gaeta GB, Coppola N., Zampino R. Parrilli G, Masarone M., Starace, Mario, Minichini, Carmine, De Pascalis, Stefania, Macera, Margherita, Occhiello, Laura, Messina, Vincenzo, Sangiovanni, Vincenzo, Adinolfi, Luigi E, Claar, Ernesto, Precone, Davide, Stornaiuolo, Gianfranca, Stanzione, Maria, Ascione, Tiziana, Caroprese, Mara, Zampino, Rosa, Parrilli, Gianpaolo, Gentile, Ivan, Brancaccio, Giuseppina, Iovinella, Vincenzo, Martini, Salvatore, Masarone, Mario, Fontanella, Luca, Masiello, Addolorata, Sagnelli, Evangelista, Punzi, Rodolfo, Salomone Megna, Angelo, Santoro, Renato, Gaeta, Giovanni B, Coppola, Nicola, Starace, M, Minichini, C, De Pascalis, S, Macera, M, Occhiello, L, Messina, V, Sangiovanni, V, Adinolfi, Le, Claar, E, Precone, D, Stornaiuolo, G, Stanzione, M, Ascione, T, Caroprese, M, Zampino, R, Parrilli, G, Gentile, I, Brancaccio, G, Iovinella, V, Martini, S, Masarone, M, Fontanella, L, Masiello, A, Sagnelli, E, Punzi, R, Salomone Megna, A, Santoro, R, Gaeta, Gb, Coppola, N., Zampino R., Parrilli G, and Masarone, M.

Subjects
0301 basic medicine, Simeprevir, Male, Hepacivirus, Viral Nonstructural Proteins, Hospitals, University, 0302 clinical medicine, Genotype, antiviral therapy, Prevalence, Treatment Failure, Sanger sequencing, Aged, 80 and over, education.field_of_study, virus diseases, Middle Aged, chronic HCV hepatitis, Infectious Diseases, Italy, symbols, DAA failure, 030211 gastroenterology & hepatology, Female, Adult, RASs, medicine.medical_specialty, Population, Mutation, Missense, Antiviral Agents, 03 medical and health sciences, symbols.namesake, Virology, Internal medicine, Drug Resistance, Viral, medicine, Humans, In patient, NS5A, education, DAAs, DAA, Aged, business.industry, Interferon free, Genetic Variation, Sequence Analysis, DNA, Hepatitis C, Chronic, digestive system diseases, Regimen, 030104 developmental biology, Amino Acid Substitution, business, RAS
Abstract

The study characterized the virological patterns and the resistance-associated substitutions (RASs) in patients with failure to IFN-free regimens enrolled in the real-life setting. All 87 consecutive HCV patients with failed IFN-free regimens, observed at the laboratory of the University of Campania, were enrolled. All patients had been treated with DAA regimens according to the HCV genotype, international guidelines, and local availability. Sanger sequencing of NS3, NS5A, and NS5B regions was performed at failure by home-made protocols. Of the 87 patients enrolled, 13 (14.9%) showed a misclassified HCV genotype, probably causing DAA failure, 16 had been treated with a sub-optimal DAA regimen, 19 with a simeprevir-based regimen and 39 with an optimal DAA regimen. A major RAS was identified more frequently in the simeprevir regimen group (68.4%) and in the optimal regimen group (74.4%) than in the sub-optimal regimen group (56.3%). The prevalence of RASs in NS3 was similar in the three groups (30.8-57.9%), that in NS5A higher in the optimal regimen group (71.8%) than in the sub-optimal regimen group (12.5%, P < 0.0001) and in the simeprevir regimen group (31.6%, P < 0.0005), and that in NS5B low in all groups (0-25%). RASs in two or more HCV regions were more frequently identified in the optimal regimen group (46.6%) than in the simeprevir-based regimen group (31.6%) and sub-optimal regimen group (18.7%). In our real-life population the prevalence of RASs was high, especially in NS3 and NS5A and in those treated with suitable DAA regimens. © 2018 Wiley Periodicals, Inc.

Published
2018

23. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

Author

Redi, D., Rossetti, B., Di Maio, V. C., Aragri, M., Paolucci, S., Masetti, C., Paglicci, L., Bruzzone, B., Minichini, C., FRANCESCA MONTAGNANI, Micheli, V., Landonio, S., Degasperi, E., Giacomo Zanelli, Maserati, R., Maida, I., Callegaro, A. P., Barbaliscia, S., Bertoli, A., Paternoster, C., Marenco, S., Morisco, F., Calvaruso, V., Taliani, G., Puoti, M., Cenderello, G., Santis, A., Lichtner, M., Coppola, N., Gulminetti, R., Cento, V., Rendina, M., Teti, E., Parruti, G., Ruggiero, T., Ghisetti, V., Pasquazzi, C., Nicolini, L. A., Vullo, V., Pellicelli, A., Prestileo, T., Cozzolongo, R., Sangiovanni, V., Biolato, M., Lenci, I., Licata, A., Ciaccio, A., Pace Palitti, V., Giorgini, A., Cariti, G., Ciancio, A., Aghemo, A., Borghi, V., Andreone, P., Brunetto, M., Pollicino, T., Santantonio, T., Cuomo, N., Caudai, C., Babudieri, S., Lampertico, P., Gaeta, G. B., Raimondo, G., Andreoni, M., Rizzardini, G., Angelico, M., Perno, C. F., Craxì, A., Maurizio Zazzi, Ceccherini- Silberstein, F., and on behalf of HCV Virology Italian Resistance Network (Vironet C)

Published
2019

24. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

Author

Di Maio, V.C., primary, Aragri, M., additional, Masetti, C., additional, Paolucci, S., additional, Bruzzone, B., additional, Degasperi, E., additional, Barbaliscia, S., additional, Pollicino, T., additional, Minichini, C., additional, Calvaruso, V., additional, Rendina, M., additional, Cento, V., additional, Teti, E., additional, Micheli, V., additional, Ghisetti, V., additional, Polilli, E., additional, Palitti, V. Pace, additional, Landonio, S., additional, Lenci, I., additional, Donnarumma, L., additional, Nicolini, L.A., additional, Bertoli, A., additional, Starace, M., additional, Pasquazzi, C., additional, Callegaro, A.P., additional, Morisco, F., additional, Cenderello, G., additional, Marenco, S., additional, Gulminetti, R., additional, Novati, S., additional, Guarneri, V., additional, Andreone, P., additional, Galli, S., additional, Ciancio, A., additional, Sangiovanni, V., additional, Cuomo, N., additional, Raddi, A., additional, Morsica, G., additional, Borghi, V., additional, Maida, I., additional, Brunetto, M., additional, Colombatto, P., additional, Cozzolongo, R., additional, De Santis, A., additional, Lichtner, M., additional, Babudieri, S., additional, Taliani, G., additional, Santantonio, T., additional, Di Stefano, M., additional, Paternoster, C., additional, Ganga, R., additional, Puoti, M., additional, Rizzardini, G., additional, Pellicelli, A., additional, Milano, E., additional, Mastroianni, C., additional, Licata, A., additional, Di Lorenzo, F., additional, Giorgini, A., additional, Lampertico, P., additional, Parruti, G., additional, Coppola, N., additional, Zazzi, M., additional, Raimondo, G., additional, Andreoni, M., additional, Craxì, A., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2019
Full Text
View/download PDF

25. The TM6SF2 E167K variant in HIV/HCV coinfection predicts severe liver fibrosis and, only for patients with HCV genotype non 3 severe steatosis

Author

SAGNELLI, Caterina, Merli, M, Uberti Foppa, C, Hasson, H, GRANDONE, Anna, CIRILLO, Grazia, Salpietro, S, Minichini, C, Starace, M, Messina, E, Parisi, Mr, MIRAGLIA DEL GIUDICE, Emanuele, Lazzarin, A, COPPOLA, Nicola, SAGNELLI, Evangelista, Sagnelli, Caterina, Merli, M, Uberti Foppa, C, Hasson, H, Grandone, Anna, Cirillo, Grazia, Salpietro, S, Minichini, C, Starace, M, Messina, E, Parisi, Mr, MIRAGLIA DEL GIUDICE, Emanuele, Lazzarin, A, Coppola, Nicola, and Sagnelli, Evangelista

Published
2016

28. In vivo evidence that the cannabinoid receptor 2-63 RR variant is associated with the acquisition and/or expansion of HIV infection

Author

Sagnelli, C, primary, Uberti-Foppa, C, additional, Hasson, H, additional, Bellini, G, additional, Minichini, C, additional, Salpietro, S, additional, Messina, E, additional, Barbanotti, D, additional, Merli, M, additional, Punzo, F, additional, Coppola, N, additional, Lazzarin, A, additional, Sagnelli, E, additional, and Rossi, F, additional

Published
2018
Full Text
View/download PDF

31. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy

Author

Marrone, A., primary, Capoluongo, N., additional, D'Amore, C., additional, Pisaturo, M., additional, Esposito, M., additional, Guastafierro, S., additional, Siniscalchi, I., additional, Macera, M., additional, Boemio, A., additional, Onorato, L., additional, Rinaldi, L., additional, Minichini, C., additional, Adinolfi, L. E., additional, Sagnelli, E., additional, Mastrullo, L., additional, and Coppola, N., additional

Published
2017
Full Text
View/download PDF

32. Liver microRNA hsa-miR-125a-5p may exert an oncosuppressor effect on HCC

Author

Onorato, L., primary, Coppola, N., additional, de Stefano, G., additional, Panella, M., additional, Iodice, V., additional, Minichini, C., additional, Mosca, N., additional, Desiato, L., additional, Farella, N., additional, Starace, M., additional, Liorre, G., additional, Potenza, N., additional, Sagnelli, E., additional, and Russo, A., additional

Published
2017
Full Text
View/download PDF

33. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network

Author

Cento, V., primary, Barbaliscia, S., additional, Di Maio, V.C., additional, Masetti, C., additional, Minichini, C., additional, Magni, C.F., additional, Micheli, V., additional, Marenco, S., additional, Nicolini, L.A., additional, Bruzzone, B., additional, Troshina, Y., additional, Baiguera, C., additional, Dentone, C., additional, Calvaruso, V., additional, Paolucci, S., additional, Melis, M., additional, Aragri, M., additional, Bertoli, A., additional, Lenci, I., additional, Landonio, S., additional, Schiavini, M., additional, Sticchi, L., additional, Ruggiero, T., additional, Polilli, E., additional, Messina, V., additional, Pellicelli, A., additional, Boglione, L., additional, Cozzolongo, R., additional, Biolato, M., additional, Morisco, F., additional, Siciliano, M., additional, Parruti, G., additional, Barbarini, G., additional, Craxì, A., additional, Babudieri, S., additional, Puoti, M., additional, Ciancio, A., additional, Rizzardini, G., additional, Coppola, N., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2017
Full Text
View/download PDF

34. An elevated degree of genetic variability characterizes Hepatitis Delta Antigen (HDAg) and correlates with high levels of serum HDV-RNA: Implication for disease progression and design of new pharmacological targets

Author

Colagrossi, L., primary, Salpini, R., additional, Scutari, R., additional, Battisti, A., additional, Piermatteo, L., additional, Bertoli, A., additional, Minichini, C., additional, Trimoulet, P., additional, Fleury, H., additional, Nebuloso, E., additional, De Cristofaro, M., additional, Cappiello, G., additional, Spanò, A., additional, Malagnino, V., additional, Mari, T., additional, Barlattani, A., additional, Iapadre, N., additional, Lichtner, M., additional, Mastroianni, C.M., additional, Lenci, I., additional, Pasquazzi, C., additional, De Sanctis, G.M., additional, Galeota Lanza, A., additional, Stanzione, M., additional, Stornaiuolo, G., additional, Marignani, M., additional, Sarmati, L., additional, Andreoni, M., additional, Angelico, M., additional, Perno, C.F., additional, Coppola, N., additional, and Svicher, V., additional

Published
2017
Full Text
View/download PDF

35. Lo studio delle onde dalla scuola dell'infanzia al termine della scuola secondaria superiore

Author

Balzano, E, Gagliardi, M, Guidoni, P, Minichini, C, Tarsitani, C., GIORDANO, ENRICA, Guidoni, P, Levrini, O, Balzano, E, Gagliardi, M, Giordano, E, Minichini, C, and Tarsitani, C

Subjects
percorso longitudinale, FIS/08 - DIDATTICA E STORIA DELLA FISICA
Abstract

Un percorso per avvicinare fin dai primi anni di scolarità all'idea di "onda" e quindi svilupparne attraverso esperienze, esperimenti e simulazioni i diversi aspetti a livelli di formalizzazione crescente.

Published
2008

36. Un esempio di percorso longitudinale: lo studio delle Onde

Author

Balzano E., Giordano E., Guidoni P., Minichini C., Tarsitani C., GAGLIARDI, MARTA PAOLA FRANCESCA, GUIDONI P., LEVRINI O., Balzano E., Gagliardi M., Giordano E., Guidoni P., Minichini C., and Tarsitani C.

Abstract

Il contributo presenta un percorso longitudinale sulle "onde", dalla scuola dell'infanzia al triennio della scuola secondaria superiore

Published
2007

37. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution

Author

Cento, V., primary, Barbaliscia, S., additional, Di Maio, V.C., additional, Masetti, C., additional, Minichini, C., additional, Magni, C.F., additional, Micheli, V., additional, Marenco, S., additional, Nicolini, L.A., additional, Bruzzone, B., additional, Troshina, Y., additional, Baiguera, C., additional, Dentone, C., additional, Calvaruso, V., additional, Paolucci, S., additional, Melis, M., additional, Aragri, M., additional, Bertoli, A., additional, Lenci, I., additional, Landonio, S., additional, Schiavini, M., additional, Sticchi, L., additional, Ruggiero, T., additional, Polilli, E., additional, Messina, V., additional, Pellicelli, A., additional, Boglione, L., additional, Cozzolongo, R., additional, Biolato, M., additional, Morisco, F., additional, Siciliano, M., additional, Parruti, G., additional, Barbarini, G., additional, Craxì, A., additional, Babudieri, S., additional, Puoti, M., additional, Ciancio, A., additional, Rizzardini, G., additional, Coppola, N., additional, Angelico, M., additional, Perno, C.F., additional, and Ceccherini-Silberstein, F., additional

Published
2017
Full Text
View/download PDF

38. Liver microRNA hsa-miR-125a-5p may exert an oncosuppressor effect on HCC

Author

Coppola, N., primary, De Stefano, G., additional, Panella, M., additional, Onorato, L., additional, Iodice, V., additional, Minichini, C., additional, Mosca, N., additional, Desiato, L., additional, Farella, N., additional, Starace, M., additional, Liorre, G., additional, Potenza, N., additional, Sagnelli, E., additional, and Russo, A., additional

Published
2017
Full Text
View/download PDF

40. HBV-HDV co-infection constrains HBV genetic evolution in HBsAg

Author

Colagrossi, L., primary, Scutari, R., additional, Salpini, R., additional, Battisti, A., additional, Pollicita, M., additional, Bertoli, A., additional, Minichini, C., additional, Trimoulet, P., additional, Fleury, H., additional, Nebuloso, E., additional, De Cristofaro, M., additional, Cappiello, G., additional, Spanò, A., additional, Malagnino, V., additional, Sarmati, L., additional, Mari, T., additional, Barlattani, A., additional, Iapadre, N., additional, Lichtner, M., additional, Mastroianni, C., additional, Lenci, I., additional, Baiocchi, L., additional, Pasquazzi, C., additional, Sanctis, G. Maria De, additional, Lanza, A.G., additional, Stanzione, M., additional, Stornaiuolo, G., additional, Marignani, M., additional, Andreoni, M., additional, Angelico, M., additional, Perno, C.F., additional, Coppola, N., additional, and Svicher, V., additional

Published
2016
Full Text
View/download PDF

45. SAT-288 - The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution

Author

Cento, V., Barbaliscia, S., Di Maio, V.C., Masetti, C., Minichini, C., Magni, C.F., Micheli, V., Marenco, S., Nicolini, L.A., Bruzzone, B., Troshina, Y., Baiguera, C., Dentone, C., Calvaruso, V., Paolucci, S., Melis, M., Aragri, M., Bertoli, A., Lenci, I., Landonio, S., Schiavini, M., Sticchi, L., Ruggiero, T., Polilli, E., Messina, V., Pellicelli, A., Boglione, L., Cozzolongo, R., Biolato, M., Morisco, F., Siciliano, M., Parruti, G., Barbarini, G., Craxì, A., Babudieri, S., Puoti, M., Ciancio, A., Rizzardini, G., Coppola, N., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.

Published
2017
Full Text
View/download PDF

47. P696 A COMPLEX HBV QUASISPECIES IN RT AND HBsAg CHARACTERIZES PATIENTS WITH ACUTE HEPATITIS B: A REFINED UDPS ANALYSIS

Author

Aragri, M., primary, Coppola, N., additional, Alteri, C., additional, Minichini, C., additional, Battisti, A., additional, Sagnelli, C., additional, Bellocchi, M.C., additional, Pisaturo, M.A., additional, Salpini, R., additional, Starace, M., additional, Continenza, F., additional, Armenia, D., additional, Carioti, L., additional, Pollicita, M., additional, Sagnelli, E., additional, Perno, C.F., additional, and Svicher, V., additional

Published
2014
Full Text
View/download PDF

48. P731 CANNABINOID RECEPTOR 2-63 QQ VARIANT IS ASSOCIATED WITH PERSISTENTLY NORMAL AMINOTRANSFERASE SERUM LEVELS IN CHRONIC HEPATITIS C

Author

Coppola, N., primary, Zampino, R., additional, Sagnelli, C., additional, Bellini, G., additional, Marrone, A., additional, Stanzione, M., additional, Capoluongo, N., additional, Boemio, A., additional, Minichini, C., additional, Adinolfi, L.E., additional, Maione, S., additional, Miraglia Del Giudice, E., additional, Sagnelli, E., additional, and Rossi, F., additional

Published
2014
Full Text
View/download PDF

49. Cannabinoid receptor 2-63 Qq variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C

Author

Coppola, N., primary, Zampino, R., additional, Sagnelli, C., additional, Bellini, G., additional, Marrone, A., additional, Stanzione, M., additional, Capoluongo, N., additional, Boemio, A., additional, Minichini, C., additional, Adinolfi, L.E., additional, Maione, S., additional, Miraglia Del Giudice, E., additional, Sagnelli, E., additional, and Rossi, F., additional

Published
2014
Full Text
View/download PDF

50. Lo studio delle onde dalla scuola dell'infanzia al termine della scuola secondaria superiore

Author

Guidoni, P, Levrini, O, Balzano, E, Gagliardi, M, Giordano, E, Minichini, C, Tarsitani, C, Tarsitani, C., GIORDANO, ENRICA, Guidoni, P, Levrini, O, Balzano, E, Gagliardi, M, Giordano, E, Minichini, C, Tarsitani, C, Tarsitani, C., and GIORDANO, ENRICA

Abstract

Un percorso per avvicinare fin dai primi anni di scolarità all'idea di "onda" e quindi svilupparne attraverso esperienze, esperimenti e simulazioni i diversi aspetti a livelli di formalizzazione crescente.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results